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Abstract
Chronic pancreatitis is an inflammatory disease that causes irreversible anatomi-
cal changes including infiltration of inflammatory cells, fibrosis and pancreatic cal-
cification with destruction of the structure of the gland, leading to abdominal pain, 
endocrine and exocrine dysfunction. Pancreatic exocrine insufficiency (PEI) preva-
lence in chronic pancreatitis varies between 40 and 94%. PEI is diagnosed by direct 
and indirect tests. Nutritional status is assessed by anthropometric indicators; labora-
tory tests—hemoglobin, plasma proteins (albumin, prealbumin, retinol- binding 
protein, transferrin), fat-soluble vitamins A, D, E, K; micronutrients. Pancreatic 
enzyme replacement therapy (PERT) is a fundamental part of PEI treatment. An 
optimal PERT could prevent serious PEI complications such as metabolic bone 
disease, adverse cardiovascular events, cachexia, poor quality of life and mortality. A 
periodic screening for PEI complications with a respect to their primary and second-
ary prophylaxis is mandatory. Diabetes mellitus secondary to pancreatic disease is 
defined as pancreatogenic diabetes or type 3c diabetes mellitus. Patients with chronic 
pancreatitis are at increased risk for pancreatic cancer influenced by smoking, 
alcohol abuse, chronic inflammation and pancreatic stellate cells over- proliferation. 
However, chronic pancreatitis could be further complicated with splenic vein throm-
bosis, pseudocysts, duodenal or biliary obstruction, pseudoaneurysm and pancreatic 
duct stones which might require endoscopic or surgical treatment.
Keywords: chronic pancreatitis, pancreatic exocrine insufficiency, enzyme 
replacement therapy, pancreatogenic diabetes, pseudocysts, splenic vein thrombosis, 
duodenal or biliary obstruction, pseudoaneurysm, pancreatic duct stones
1. Introduction
Chronic pancreatitis (CP) is an inflammatory disease that causes irreversible 
anatomical changes and damage including infiltration of inflammatory cells, 
fibrotic processes and calcifications formation with destruction of the gland 
structure and thus affects normal nutrients digestion and absorption. The clinically 
early phase is characterized by pain and recurrent acute pancreatitis episodes and 
complications, and the late phase by exo- and/or endocrine insufficiency. In 2016, a 
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new definition of CP was proposed, according to which CP is a fibro-inflammatory 
syndrome, affecting people with genetic, environmental and/or other risk factors, 
resulting in a persistent pathological response as a result of parenchymal injury or 
stress. In addition, some of the following features of advanced CP may be present in 
each patient: pancreatic atrophy, fibrosis, pain syndrome, ductal stricture, calcifica-
tions, pancreatic exocrine/endocrine insufficiency and dysplasia. The frequency of 
CP per year in the European population is 5–10/100,000. Alcohol abuse is the most 
observed cause. Recurrent episodes of acute pancreatitis and heredity as a contrib-
uting factor may result into CP development [1–7].
Pain is the most frequent symptom in CP patients, leading to quality of life 
impairment. It pathogenesis is still poorly understood. Multimodal approach, 
including lifestyle changes, medical therapy, pancreatic endoscopic and surgical 
procedures, and other non-pharmacological options are recommended [8, 9].
The pancreatic enzymes lipase, amylase, trypsin and chymotrypsin, released 
predominantly by the duodenal mucosa exposure of nutrients—especially lipids, 
are at a great importance for the macronutrient digestion. Their secretion comprises 
the following three phases—maximum, stable and basic secretion. Pancreatic 
enzymes amount and action duration depend on the caloric content maldigestion, 
the food type and its physical properties [1, 6, 7, 10, 11].
Pancreatic exocrine insufficiency (PEI) due to a progressive loss of acinar cells is 
a functional limitation of pancreatic enzyme and bicarbonate secretion, regardless 
its etiology, leading to digestive process deficiency. Main pathological mechanisms 
in adults are (1) Insufficient pancreatic secretory capacity, (2) Decreased gland 
stimulation, (3) Impaired enzymes release in the duodenum. The causes are divided 
into primary (chronic pancreatitis, cystic fibrosis, pancreatic agenesia, congeni-
tal pancreatic hypoplasia, Shwachman-Diamond syndrome, Johanson-Blizzard 
syndrome, pancreatic lipomatosis or atrophy, isolated lipase or co-lipase deficiency, 
pancreatic carcinoma, pancreatic resection) and secondary (reduced cholecysto-
kinin releasing, somatostatinoma or exogenous administration of somatostatin, 
gastrinoma, (sub) total gastrectomy, resections and Billroth II anastomosis, periam-
pullary tumors) [11–15].
Although not studied in-depth, the reported prevalence of PEI in patients 
with CP varies widely between 40 and 94%. The onset of PEI depends on the CP 
etiology and is about 10–15 years (5–6 years for alcoholic CP) after initiating the 
pathological CP processes, which is explained by the large functional reserve capac-
ity. Decompensation occurs when the enzyme secretion is reduced by 90–95%. 
However, in some patients PEI symptoms such as malnutrition and/or abdominal 
symptoms (diarrhea, flatulence, pain), steatorrhea, body weight loss are first 
appearance of the disease [1, 7, 16–18].
Although steatorrhea is a typical symptom of a severe PEI, no clinical symp-
tom unambiguously proves or excludes PEI. Steatorrhea may be absent or caused 
by pancreatic duct obstruction, low duodenal pH, decreased contact time due 
to increased motility, small intestinal bacterial overgrowth. Fat-soluble vitamin 
insufficiency, protein malnutrition, increased risk of osteoporosis and fractures, 
life-threatening complications such as cardiovascular events are further PEI 
 complications [2, 5, 19–22].
An up-to-date assessment of pancreatic exocrine function allows diagnosis 
of PEI, initiation of pancreatic enzyme replacement therapy (PERT) and its 
monitoring. Pancreatic exocrine secretion can be assessed by direct and indirect 
methods. Direct tests are based on determination of volume, bicarbonates and/
or enzymes in the stimulated pancreatic gland by intravenous administration of 
hormones or their peptide analogs. These methods are invasive because duodenal 
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intubation and a duodenal juice sample are required. Most indirect methods, 
which evaluate either the digestive ability of the pancreas or the pancreatic secre-
tion by quantification of pancreatic enzymes, are non-invasive, but some require 
blood sampling and are then considered invasive. The clinical benefit of each 
method is based on diagnostic accuracy, relevance in clinical practice and cost 
[20, 23–25].
Pancreatic enzyme replacement therapy is an essential part of PEI treatment. 
Nowadays a majority of patients with PEI might be asymptomatic, receiving none 
or suboptimal PERT. They are at increased risk of PEI complications and impaired 
quality of life. Patients’ compliance should be ensured. Periodical monitoring of 
PERT by nutritional assessment and BMI is mandatory with a respect to primary 
and secondary prophylaxis of risk factors [1, 6, 18, 26–30].
Pancreatogenic diabetes or type 3c diabetes mellitus develops secondary to 
pancreatic disease. Recently, DM type 3c is a more recognizable entity due to new 
proposed criteria. It is a complex disease, further complicated by the presence of 
comorbidities such as maldigestion and accompanying malnutrition. Metformin is 
a treatment of choice. Annually screening for type 3c DM by fasting glucose levels 
and HbA1c is of a great importance in patients with CP regardless the grade of 
pathological structural changes [17, 18, 20, 31, 32].
Many studies are conducted to demonstrate the association between CP with 
tropical and hereditary etiology and DM with pancreatic cancer development. 
The pathogenesis of malignant transformation on the basis of CP remains unclear. 
Biomarkers and imaging modalities are used to distinguish inflammation form 
neoplasia [33, 34].
The management of the miscellaneous CP complications pseudocysts, splenic vein 
thrombosis, duodenal and biliary obstruction, pseudoaneurysm, pancreatic calculi 
consists of their screening and treating [23].
2. Clinical manifestations of chronic pancreatitis and their management
2.1 Abdominal pain
Abdominal pain is a predominant symptom, affecting 80–90% of patients with 
CP. Pain significantly reduce quality of life. Pathogenesis is still poorly understood. 
Multifactorial mechanisms are proposed, including inflammation; duct obstruction 
followed by hypertension and ischemia; neuronal damage—neuropathic and dys-
functional pain due to hypersensitivity, central and spinal nociceptive neurons alter-
ations. Alcohol and tobacco have contributing role for pain exacerbation. Pancreatic 
pain covers the characteristics of visceral pain—diffuse severe dull persistent pain, 
usually with epigastrium location and further radiation to the back, left or right 
hypochondria. Pain is not necessarily linked to a new acute episode and often wors-
ens with food intake. Pain could be recurrent, during acute episodes and prolonged. 
Questionnaire scales could be used for pain characterization: Izbicki pain score, brief 
pain inventory (validated for CP), quantitative sensory testing. According to newest 
guidelines a multi-modal approach, including lifestyle changes, medical therapy and 
non-pharmacological approaches, is recommended. Alcohol and tobacco cessation 
should be advised in all patients. PERT could release pain in patients with ductal 
obstruction as oral enzymes reduce cholecystokinin levels and therefore decrease 
pancreatic juice secretion, leading otherwise to duct hypertension. A combination 
of antioxidants is useful to reduce the oxidative stress and damage. According to 
the published in 1986 WHO stepwise analgesic’s approach is recommended. Simple 
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analgesics (Paracetamol, NSAIDs, Aspirin) are first-line drugs with Paracetamol 
being the preferable one. If no pain relief is achieved, weak opioids (Tramadol), 
strong opioids (Morphine, Oxycodone), gabapentinoids (Pregabalin), antidepres-
sants or N-methyl-d-aspartate receptor antagonists (Ketamine) could be used. 
Endoscopic treatment with or without Extracorporeal Shock Wave Lithotripsy has 
a beneficial role in cases with duct obstruction (see below). If endoscopic treatment 
is ineffective, surgery procedures (drainage, partial or total resection) are indicated. 
Better results are observed, when applied in early stages of CP and in patients with 
no opioids requirements. Other non-pharmacological options in selected patients 
include bilateral thoracoscopic splanchnicectomy, celiac plexus blocks and splanch-
nic nerve ablation, spinal cord stimulation, transcranial magnetic stimulation, 
psychological therapies [8, 9].
2.2 Pancreatic exocrine insufficiency
2.2.1 Pancreatic exocrine insufficiency assessment by direct functional tests
2.2.1.1 Secretin stimulation test
Hormonal stimulation tests are considered to be the most sensitive and specific 
tests that investigate pancreatic function, including chronic pancreatitis. The test, 
introduced by Dreiling in 1948, is based on the physiological pancreatic stimulation 
by secretin with release of water and bicarbonates from the centroacinar and ductal 
cells. The volume of the duodenum aspiration and bicarbonate concentration are 
evaluated after double lumen duodenal tube insertion. Standardized ranges, which 
exclude pancreatic exocrine insufficiency, are: 80–130 mEq/L for peak bicarbonate 
concentration; 10.1–37.0 mEq/h bicarbonate output, and volume 1.5–5.7 mL/kg for 
volume/kg. The patient is most likely to suffer from CP if the peak bicarbonate con-
centration is less than 80 mEq/L. The sensitivity of the test ranges between 60 and 
94% and the specificity between 67 and 95%. In a growing number of publications, 
the use of secretin in the course of other techniques (secretin-enhanced MRCP or 
endoscopic secretin testing) demonstrates the ability for evaluation of minimal 
structural changes in the pancreas, in contrast to standard imaging methods which 
fail to diagnose them [35–38].
2.2.1.2 Cholecystokinin stimulation testing
The classical cholecystokinin stimulation test was developed and first used 
in the Mayo Clinic. The test measures the enzyme output. Cholecystokinin is 
given as a continuous infusion of 40 ng/kg/h, but can also be administered as a 
bolus. Cholecystokinin increases bile secretion in the duodenum during the first 
20–40 min after administration, and as a result, the measurement of pancreatic 
secretion might be affected. The cholecystokinin test disadvantages are as follows: 
a need for simultaneous gastric and duodenal juices collection during intubation, 
duodenal perfusion of mannitol and polyethylene glycol solution, delayed stomach 
emptying, mediation of pain, symptoms of nausea and vomiting most probably due 
to blood–brain barrier passage [35, 39–43].
2.2.1.3 Secretin-cholecystokinin testing
The combined secretin-cholecystokinin stimulation testing, also called the 
secretin-pancreozymin test, allows the simultaneous measurement of secretion of 
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both bicarbonate and enzyme by the pancreatic gland. However, cholecystokinin 
may be administered before or after secretion as long as there is no international 
standard for test performing and it seems to play insignificant role for diagnostic 
accuracy. Like the classic cholecystokinin test, it increases the secretion of bile in the 
duodenum [24, 35, 44].
2.2.1.4 Endoscopic testing
After introducing the idea of obtaining pure pancreatic juice during ERCP 
in 1982, the technique was adopted and modified by the Japanese pancreatic 
group and the Cleveland Clinic researchers. The pancreatic fluid collected dur-
ing ERCP has a higher bicarbonate concentration compared with the classic 
secretin test (130 mEq/L for healthy subjects and less than 105 mEq/L for CP) 
and is not contaminated with bile and duodenal content. The drawbacks of the 
method are the potential ERCP complications, the relatively short time for sample 
collection—15 min and the need for sedation, which can affect pancreatic secre-
tion. Therefore, the collection of duodenal juice after secretin with or without 
cholecystokinin stimulation during a standard endoscopic procedure with a tube 
placed in the endoscope biopsy canal was developed as a comparable alternative. 
The peak of bicarbonate concentration and the lipolytic activity in the duodenal 
juice are significantly lower in patients with CP. However, experts find bicar-
bonate and enzyme output to be more reliable markers for exocrine pancreatic 
function. Due to its nature—invasiveness, labor intensity, length of procedure 
(endoscope placement in the duodenum for 1 h) and price, the use of endoscopic 
tests is limited to some specialized centers, so they are not widely used in every-
day practice [24, 39, 45].
2.2.1.5 Secretin-enhanced MRCP (s-MRCP)
Secretin-enhanced MRCP becomes more and more interesting as a method 
of visualization and morphological assessment of the pancreatic structure, as 
well as for quantitative assessment of various aspects of pancreatic exocrine 
function. The magnetic resonance technique has a number of advantages: lack 
of invasiveness, safety, possibility of three-dimensional reconstruction. The 
method is costly and is currently limited to large centers, where it is often used in 
combination with other tests. Its sensitivity is about 90% and is a reliable method 
for diagnosis of CP in an early stage. In CP, fibrous tissue gradually replaces 
the glandular elements in the pancreas. This process is reflected in the s-MRCP 
through characteristic changes in the major pancreatic duct (presence or absence 
of dilated main pancreatic duct >1 mm), peripheral branches (the presence or 
absence of dilated peripheral branches) and the volume of pancreatic secretion. 
The method enables the diagnosis of pancreatic divisum, pseudocysts, ductal 
disruption resulting from pancreatic necrosis or trauma. For the pancreatic 
functional evaluation a semiquantitative assessment of the duodenal filling with 
pancreatic juice at 10th min after secretin application is performed by the fol-
lowing criteria: grade 0-missing duodenal filling; grade 1-only bulbus duodeni 
filling; grade 2-filling up to genu inferior duodeni; grade 3-fluid filling after genu 
inferior duodeni. Grade 0–2 is assumed to demonstrate reduced exocrine func-
tion. During S-MRCP volume of pancreatic output is predominantly measured. 
That is why sphincter of Oddi spasm or obstructive lesions may lead to false CP 
diagnosis. Because of the technique performance and duration the sensitivity 
could be reduced [35, 46–51].
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2.2.2 Pancreatic exocrine insufficiency assessment by indirect functional tests
Indirect pancreatic tests are available in clinical practice and are therefore 
more common. Indirect tests assess pancreatic exocrine function by quantifying 
pancreatic digestive ability or pancreatic enzyme levels in feces. The sensitivity and 
specificity of these indirect tests are variable and lower than the direct ones espe-
cially in mild and moderate PEI. From a methodological point of view, tests can be 
classified as oral and fecal tests.
In the oral tests, the substrate is given per os along with test meal. Pancreatic 
enzymes hydrolyze the substrate in the duodenum, and released metabolites are 
absorbed from the intestine, metabolized in the liver and therefore they can be 
measured in serum, urine or exhaled air. Various extrapancreatic causes could limit 
the accuracy of oral pancreatic tests, mainly by interfering with normal digestion: 
reduced gastric emptying, biliary secretion and/or intestinal absorption due to 
intestinal disease. Impaired gastric emptying may be affected by the administration 
of metoclopramide or another prokinetic (cisapride, domperidone etc.) [24, 35].
2.2.2.1 13C-mixed triglycerides breath test
The first oral test for fat malabsorption assessment is based on the use of radio-
active iodine 131triolein as a substrate. Modern oral tests use non-radioactive sub-
strates the mixed triglyceride test 13C-MTG-breath test, cholesteryl 13C-octanoate, 
13C-hyolein and 13C-triolein. Most commonly used and with the most optimal 
substrate is the only one optimized so far 13C-MTG breath test, which was intro-
duced into clinical practice by Vantrappen et al. in 1989 and develops as a simple 
alternative to fecal fat quantification. The test directly measures clinically the most 
significant effect of exocrine pancreatic function: degradation of triglycerides. 
Following the already explained metabolic pathway of the labeled substrate in oral 
tests, 13CO2 is released and eliminated together with the exhaled air and measured 
by near-infrared analysis or mass spectrometry. Patients with PEI have decreased 
lipase activity, which can be detected by reduced elimination of 13CO2 in the exhaled 
air. The 13C-MTG breath test sensitivity for PEI verification is higher than 90%. 
The current mostly adopted and used protocol is the one developed by Domínguez-
Muñoz et al. PEI is diagnosed if values are below 29%. The 13C-MTG breath test 
is an easy, non-invasive and accurate method of PEI diagnosis. The test is easily 
applicable in clinical practice and can be repeated as often as necessary. It is also 
used to monitor the enzyme replacement therapy [24, 52–56].
Fecal tests are based on the quantification of pancreatic enzyme concentration 
(fecal elastase-1) or activity (chymotrypsin) in feces. Enzymes are deactivated and 
diluted or concentrated during the intestinal passage, which should be taken into 
account when interpreting the results [24, 35].
2.2.2.2 Fecal chymotrypsin activity
The test is based on the determination of chymotrypsin activity in a single fecal 
sample. Fecal chymotrypsin activity lower than 3 U/g is indicative of PEI, but the 
sensitivity of the test is low. The test is normal in cases of mild CP and in about half 
of cases with moderate or severe pancreatitis. Significant disadvantages of the test 
are partial enzyme inactivation during gastrointestinal passage; reduced activity 
in patients with diarrhea. Quantitative determination of chymotrypsin in feces is 
an accessible way to assess patient complicity according to the taken replacement 
therapy as fecal chymotrypsin activity should be significantly increased if oral 
therapy is administered correctly [24, 35, 57].
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2.2.2.3 Fecal elastase-1
The protease elastase represents about 6% of the pancreatic enzyme secre-
tion. Determination of Fecal Elastase-1 (FE-1) is the most common PEI screening 
test as the enzyme is stable during passage through the gastrointestinal tract, its 
levels correlate with the secreted amount of the pancreas and the direct func-
tional assays. Even though the determination of FE-1 does not offer a significant 
advantage over other indirect functional tests, its easy conduction makes it a first 
step pancreatic function screening tool. FE-1 is determined by monoclonal or 
polyclonal antibodies ELISA tests. The advantage of monoclonal antibody test 
is its accuracy during enzyme replacement therapy intake. FE-1 concentrations 
below 200 μg/g feces indicate PEI, and severe PEI is considered if FE-1 is below 
100 μg/g (according to some authors below 50 or even 15 μg/g). The specificity of 
the test is 93%. Diagnostic sensitivity varies between 54 and 63% in mild pancre-
atic insufficiency and reaches 82–100% in moderate and severe form. Low levels 
of FE-1 correlate with morphological changes in CP, objectivized by ERCP and 
MRCP. Determination of FE-1 is very important and useful in children at the age 
of 2 months with cystic fibrosis. False positive FE-1 results have been reported in 
the presence of diarrhea, villous atrophy or a strict vegetarian diet prior to testing 
[24, 35, 57–62].
2.2.2.4 Steatorrhea-based methods
The amount of released fat in the feces indirectly reflects the degree of fat diges-
tion and thus the secretion of pancreatic lipase. The steatorrhea-based methods 
are divided into: qualitative (direct microscopy of Sudan III stained preparations), 
semiquantitative (steatocrit and semiquantitative determination by Sudan III stain-
ing) and quantitative (coefficient of fat absorption).
A single fecal sample is used for Sudan III staining. The methodology is based 
on the number and size of fat drops by high-power field (hpf). The accepted 
normal ranges are the presence of ≤20 fat drops sized 1–4 μm/hpf. Sudan staining 
has a sensitivity of up to 94% and 95% specificity for the diagnosis of abnormal fat 
 excretion [35, 63].
Steatocrit is a method for semi-quantitative measurement of fats in feces, 
expressed as a proportion of the fat content of a single centrifuged and homog-
enized feces sample. The single determination of acid steatocrit (normal values 
below 10%) has been shown to have 100% sensitivity for steatorrhea detection and 
95% specificity when compared to a 72-h quantitative fat assay [64, 65].
The most reliable and recommended steatorrhea detection method is the 72-h 
chemical analysis using the van de Kamer method. Many technique modifications 
have been made so far but still the disadvantages to use large amounts of acids and 
bases, the manual manipulation of the analysis, the need for additional equipment 
and specially trained staff remain. However, Near-Infrared Reflectance Analysis 
(NIRA) methodology, based on the relationship between the intensity of the 
refractive spectrum of the fecal specimen at a specific wave length and the sample 
composition, is an alternative, that simplifies and aids application of the study in 
clinical practice [24, 66].
The coefficient of fat absorption (CFA) is used for a better steatorrhea char-
acterization. The CFA is calculated by the following equation: CFA (%) = 100 × 
[(mean fat value − mean fat in feces)/average fat intake]. In healthy people CFA 
is usually over 80%. The technique has a number of disadvantages, that reduce its 
everyday applicability—a standard diet containing 80–120 g of fat daily for five 
consecutive days, collection of entire amount of feces from the last 3 days of the 
Pancreatitis
8
diet, inconvenience during feces storing in laboratories, low specificity (any other 
cause of maldigestion or malabsorption can lead to abnormal fecal fat excretion) 
[35, 67, 68].
2.2.2.5 Serum trypsin
The trypsin test is the only currently functional diagnostic test that can be 
performed in serum. Low concentrations of less than 20 ng/mL are specific for 
CP, but are only sensitive to advanced stage of disease. Levels ranged from 20 to 
29 are intermediate, but in some cases may point to an early CP. The sensitivity of 
the method varies with mild and severe stages of the disease and is between 33 and 
65% while the specificity is high. Another advantage of trypsin is that levels above 
150 ng/mL are indicative of pancreatic inflammation even in the case of normal 
amylase and lipase levels [69].
2.2.3 Evaluation of nutritional status as a PEI marker
Malnutrition is a major clinical consequence of PEI. Lindkvist et al. studied 
114 patients with CP (EUS, MRCP), 33% suffered from PEI according to 13C-MTG 
breath test. Hemoglobin, albumin, prealbumin and retinol-binding protein (RBP) 
levels below reference limit, magnesium less than 2.05 mg/dL and HbA1C above 
the upper reference limit are associated with PEI. A normal panel of these serum 
nutritional markers excludes PEI with a high negative predictive value. In case of an 
abnormality, these parameters serve as a marker for initiating PERT. Their follow-
up would indicate the need to adjust the dose of PERT [1, 4, 70].
2.2.4 Pancreatic exocrine insufficiency treatment
Fundamental aspects of PEI treatment, ensuring an optimal therapeutic effect, 
include pancreatic enzyme replacement therapy (PERT), smoking and alcohol 
consumption cessation, frequent small meals with a normal fats intake, fat-soluble 
vitamins and a systemic follow-up with respect to BMI and nutritional markers. The 
main aim of PEI treatment is, while compensating the lack of endogenous enzyme 
secretion including lipolysis, to avoid malabsorption and steatorrhea, decrease 
complications severity, and prevent the associated with malnutrition morbidity and 
mortality as well as disease progression [1, 7, 18, 20, 26, 71, 72].
Pancreatic enzyme preparations are extracts of porcine pancreas (pancrelipase 
or pancreatin) with main components: lipase, amylase, trypsin and chymotrypsin. 
Their alternatives are bovine enzymes, lipase of mushroom origin, bacterial lipase 
and human lipase. The pancreatic digestive enzymes in PERT are administered 
orally together with the meal to ensure the mixing of pancreatin with the humus 
[1, 7, 11, 18, 26, 27, 71, 73, 74].
Currently, the main formulations of the enzyme preparations are with immedi-
ate release, enteric-coated microspheres and minimicrospheres, enteric-coated 
microtablets and enteric-coated microspheres with bicarbonate buffer. The most 
widely used enzyme preparations are administered as acid-resistant enteric-coated 
minimicrospheres with a pH-related release. Currently, none of the approved 
enzyme supplements are specifically designed for use through percutaneous 
gastrostomy. In infants and patients who cannot swallow large capsules, opening 
the capsules in a small amount of acidic foods is an acceptable way to administer the 
drug [1, 2, 12, 75–77].
Although not systematically studied in clinical trials, based on recommenda-
tions from different national associations the starting dose of PERT ranges between 
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20,000 to 50,000 IU lipase per main course and half the dose per snacks, which 
corresponds to about 5–10% of the cumulative lipase activity in the duodenum 
after normal meal. PERT is well tolerated with no serious adverse events reported. 
Fibrosing colonopathy is the only serious complication associated with a high PERT 
dose. Cases of fibrosing colonopathy have been significantly reduced following the 
recommendation that PERT should not exceed 10,000 IU lipase/kg/day in patients 
since 1994 [6, 18, 20, 25, 78–82].
Of a great importance is to ensure patient’s compliance. If the signs or symptoms 
of maldigestion persist, the dose of PERT may be increased twice or three times. 
As e next step for optimal pH release of enzymes and to influence the precipitation 
of bile acids and prevent lipase degradation, proton pump inhibitors/antacids/H2 
blockers/prostaglandin analogs can be added. If PERT results are still insufficient, 
diagnosis revision is required in respect to concomitant and/or alternative causes for 
maldigestion (small intestine bacterial overgrowth, biliary salt deficiency, gastric 
resection, therapy with certain medications (nonsteroidal anti-inflammatory drugs, 
antacids). Up to 40% of PEI patients with CP have concomitant small intestinal 
bacterial overgrowth. Import of 35 kcal/kg/day is required as protein intake of 
1.0–1.5 g/kg/day is usually sufficient. Small frequent meals (4–8 times/day) are 
generally more tolerable than high-calorie meals due to the more effective mixing 
of the enzyme preparations with the humus. In the modern nutritional concept of 
PEI no fat restrictions are advisable to reduce the risk of weight loss and deficiency 
of fat-soluble vitamins. In addition, studies show that corresponding substance 
presence increases the half-life of the enzyme activity in small intestine [1, 5, 6, 18, 
20, 25, 27, 73, 83–87].
Oral, enteral and parenteral nutrition are needed in about 10–15, 5 and 1% of 
patients respectively, usually in case of disease complications (gastric obstruction) 
prior to surgery or for a short period of time in patients with advanced exocrine 
insufficiency [4, 20, 25, 79, 88, 89].
Alcohol and tobacco cessation are of a great importance as they are associated 
with development of pancreatic cancer, acute and chronic pancreatitis, deterioration 
of pancreatic exocrine function as shown by endoscopic functional tests in CP cases. 
Earlier development of calcified pancreatitis and diabetes mellitus are observed in 
patients with prolonged smoking. Physical activity and a healthy life style along with 
nutritional therapy should be encouraged for optimal outcome [1, 7, 20, 27, 90].
Most leading researchers recommend a reassessment of symptoms, BMI and 
serum malnutrition tests with long-term normalization of vitamin status for deter-
mining success of PEI treatment. In recent years, studies have shown widespread 
nutritional deficiencies (fat-soluble vitamins, prealbumin, retinol-binding protein 
(RBP), and magnesium) in patients with PEI with or without symptoms, which 
are associated with many risk factors, including malabsorption, diabetes mellitus 
and alcoholism. Protein markers prealbumin and RBP correlate with age, BMI, 
morphological changes, fat-soluble vitamins, albumin, hemoglobin, magnesium. 
According to the United European Gastroenterology evidence based guidelines for 
the diagnosis and therapy of CP (HaPanEU), PERT should be initiated in patients 
with PEI in the presence of clinical symptoms or nutritional deficiencies. By PERT 
optimization in patients with suboptimal dosage an improvement in the nutritional 
markers is observed [1, 7, 18, 20, 25, 26, 72, 79, 91–95].
Deficiency of vitamins A, D, E, K correlates with the severity of steatorrhea in 
patients with CP and PEI, but can be caused by various mechanisms, including fat 
malabsorption, suboptimal nutrition, higher losses or requirements, nutrient deple-
tion, antioxidant activity. Vitamin A, D, E and K deficiency are observed in 3, 53, 
10 and 63% of patients (Sikkens et al.) with no clinical manifestations of vitamin 
E deficiency in up to 75% of CP patients. It has been established that the severity 
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of CP (according to the Cambridge classification) correlates with the bone mineral 
density of the spine and the femoral neck. Patients with CP regardless their exo-
crine status have more often than expected reduced bone mineral density as shown 
in a recent meta-analysis: 1 in 4 patients were diagnosed with osteoporosis and 2/3 
with osteopathy. Risk factors for fractures include female gender, older patients 
(the relative risk is higher in younger patients), smoking, alcohol consumption 
(60–150% greater risk than non-alcoholic CP patients), chronic inflammation, low 
BMI regardless of bone mineral density. The incidence of fractures after minimal 
trauma among CP patients is comparable and even higher than in patients with 
high-risk gastrointestinal diseases (Crohn’s disease, cirrhosis, celiac disease, after 
gastrectomy), for which guidelines for osteoporosis screening exists. The treatment 
of osteopathy should be carried out in accordance with up-to-date guidelines on the 
treatment of metabolic bone disease in the general population [2, 14, 16, 27, 28, 59, 
65, 96–103].
In addition to bone metabolism, vitamin D is a factor in the development of 
pancreatic fibrosis and atrophy, cardiovascular and autoimmune diseases, type 1 
and 2 diabetes mellitus, and contributes to an increased overall mortality [104, 105].
Due to insufficient protease secretion from the pancreas, vitamin B12 deficiency 
may occur. Micronutrient deficiencies have been reported as well: zinc (especially in 
diabetes mellitus), calcium (normal levels in patients receiving PERT), magnesium, 
thiamine and folic acid, riboflavin, choline, manganese, sulfur, copper and others 
[106–108].
The assessment of fat-soluble vitamins, minerals and trace elements and bone 
density should be monitored 1–2 times a year [109].
2.2.5 Cardiovascular risk evaluation
A recent study observed increased mortality in patients with PEI. Patients who 
died used to have a worse nutritional status. However, an optimal PERT is essen-
tial to reduce morbidity and mortality associated with CP. Maldigestion is associ-
ated with life-threatening complications such as cardiovascular, cachexia, which 
are related to low plasma levels of the cardioprotective HDL, apolipoprotein 
(apo) A-I and lipoprotein A (2). In a recent study in patients with CP who had not 
received PERT, mean triglyceride levels were found to be significantly higher in 
patients with PEI than those without PEI. According to randomized clinical trials, 
mean levels of cholesterol, HDL, LDL and triglycerides in patients with CP and 
PEI receiving PERT have been reported in reference ranges. Based on American, 
European and Canadian guidelines, a complex approach, including screening 
systems, lipid profile, apolipoproteins, is needed to properly assess cardiovascular 
risk. Apolipoprotein B as part of all atherogenic or potentially atherogenic parti-
cles including LDL, VLDL, IDL, lipoprotein (a) (each particle contains 1 molecule 
of apo B) provides direct measurement of all atherogenic lipoprotein particles in 
the circulation, which makes apo B more reliable indicator of cardiovascular risk 
than LDL. Clinical and epidemiological studies confirm that apo B and Apo B/
Apo A-I ratio are associated with a worse outcome in patients with cardiovascular 
diseases and are supposed to predict cardiovascular incidents more accurately 
than the routinely tested cholesterol, LDL, TC/HDL, non-HDL. The proposed 
cut-off values for Apo B/ApoA-I ratio predicting high cardiovascular risk (acute 
myocardial infarction) are 0.9 for men and 0.8 for women. In patients with Apo 
B/ApoA-I ratio higher than 0.9, higher triglyceride levels and plasma atherogenic 
index and lower apo E were found. A study demonstrates an increased risk of 
myocardial infarction using Apo B/Apo A-I ratio in patients with CP [1, 5, 7, 79, 
89, 110–131].
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Apolipoprotein A, which is the main apolipoprotein associated with HDL, has 
two forms—apo A-I and apo A-II. The levels of apolipoprotein A-I are strongly 
related to those of HDL and can serve for plasma HDL level determination. In 
a recent study, an impaired nutritional status with decreased prealbumin, RBP, 
hemoglobin, magnesium has been found to significantly relate to low apoA-I and 
apoA-II levels with a tendency of increased apo B/apo A-I ratio, which does not 
reach a significant value. Apolipoprotein C-III inhibits the lipolysis of triglyceride-
rich lipoproteins and complicates their elimination from the bloodstream. High 
levels of apolipoprotein C-III are associated with an increased risk of cardiovas-
cular events and atherogenesis. Lower apolipoprotein C-III levels are observed by 
morphological changes worsening in CP. The metabolic and inflammatory status 
in patients with CP can be traced with great accuracy by examining a protein panel 
of retinol binding protein, serum amyloid-alpha, Apo A-II, Apo A-I, Apo C-I, Apo 
C-II, Apo C-III and prealbumin, which are significantly more reduced than the 
controls (Hartmann et al.). The observed changes may be associated with underly-
ing malnutrition/cachexia, which phenomena are known in the modulation of the 
synthesis of acute phase proteins in acute or chronic disease [112, 119, 127, 128, 130, 
132–137].
2.3 Pancreatic endocrine insufficiency
In respect to its etiology, the diabetes mellitus (DM), which is caused by 
pancreatic diseases, is defined by the American Diabetes Association (ADA) and 
World Health Organization as pancreatogenic diabetes or Type 3c DM and is 
included in “other specific forms of diabetes” (ADA). About 5–10% of all diabetic 
patients in Western populations fulfill the criteria for pancreatogenic DM, of 
which circa 80% have underlying CP. The prevalence and clinical significance 
of DM secondary to CP has been recently underestimated. The median survival 
is 8.7 years after diagnosing type 3c DM. Chronic pancreatitis and DM are inde-
pendent risk factors for pancreatic cancer development. While the presence of 
anti-insulin antibodies and clinical or biochemical data on insulin resistance are 
associated with type 1 and 2 DM respectively, the pathogenesis of type 3c DM is 
very complex. According to the recommendations of Rickels MR et al. from the 
Pancreas Fest 2012, the following criteria for the diagnosis of type 3c DM were 
proposed. Major criteria (all must be fulfilled): (1) Pancreatic exocrine insuf-
ficiency. (2) Pathological pancreas imaging (EUS, MRI, CT). (3) Lack of type 1 
DM associated with the presence of autoantibodies. Minor criteria: (1) Impaired 
beta-cell function (HOMA-B, C-peptide/glucose ratio). (2) Lack of insulin resis-
tance (HOMA-IR). (3) Invasive secretion disorder (GLP-1, pancreatic polypep-
tide). (4) Low levels of serum fat-soluble vitamins (A, D, E, K). Because of loss of 
glucagon response to hypoglycemia and low carbohydrate levels (malabsorption; 
inadequate food intake due to pain, nausea and/or chronic alcohol abuse), patients 
with type 3c DM may experience frequent episodes of hypoglycemia, making the 
glucose control challenging. The course of the disease is further complicated by the 
presence of comorbidities such as maldigestion and accompanying malnutrition. 
Metformin, which is recommend as first-line treatment for type 2 DM by ADA 
and EASD, has been shown to reduce the risk of pancreatic cancer by 70% and the 
associated mortality, making metformin suitable therapeutic option for type 3c 
DM patients. The associated with an increased risk of developing pancreatitis as 
well as numerous gastrointestinal side effects (nausea, delayed gastric emptying, 
weight loss) GLP-1 analogues and DPP4-inhibitors should be avoided as long as 
their safety and benefits are proven. Impaired incretin hormone secretion can 
be normalized by supplementation with pancreatic enzymes, which is reflected 
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in improved insulin secretion and glucose tolerance during meals. Adequate oral 
enzyme replacement affects steatorrhea, prevents malnutrition and metabolic 
complications. In patients with severe malnutrition, insulin therapy is a first-line 
of choice because of the anabolic effect of insulin. The association of low levels 
of vitamin D and poor glycemic control draws attention to the need to normal-
ize vitamin status in patients with type 3c DM. Diagnosis and monitoring of 
DM should be consistent with the endocrinology societies guidelines. Annually 
screening for type 3c DM by fasting glucose and HbA1c is of a great importance in 
patients with CP regardless the grade of pathological structural changes [18, 20, 
25, 31, 32, 122, 138–143].
3. Chronic pancreatitis complications and their management
3.1 Pancreatic cancer
Since the first report by Rocca et al. in 1987 for an increased incidence of 
pancreatic cancer (PC) in patients with CP, several epidemiological studies have 
identified that CP, mainly tropical and hereditary pancreatitis, is a major risk factor 
for pancreatic cancer development. Augustine et al. reported that PC is affecting 
8.3% of patients with CP with a roughly 100-fold higher incidence compared to 
patients without tropical pancreatitis. Younger patients are affected and have a 
worse outcome. In hereditary CP due to multiple PRSS1 mutations the lifetime risk 
for PC is 40–55% by the age of 70. Possible explanations for the increased neoplastic 
transformation risk are the onset of CP at younger age and its long duration. Various 
risk factors for PC development have been described, of which smoking is the major 
one. In a recent study, Hao et al. (2017) suggest that age at the onset of CP (hazard 
ratio, 1.05) and a > 60 pack-year smoking history (hazard ratio, 11.83) are PC risk 
factors. CP as an inflammatory disease is associated with higher cell turnover with/
without DNA damage, progressing to oncogenic mutations in K-ras, p16 and p53 
promoting metaplasia and neoplastic degeneration. Another well-known PC risk 
factor is diabetes mellitus. Ethanol and its metabolites are supposed to activate 
pancreatic stellate cells over-proliferation. They play a role in tumor progression 
and chemotherapy resistance. Moreover, cholecystokinin receptors are abnormally 
over-produced. Clinical features may mimic those of CP in early stages. When 
symptoms such as obstructive jaundice, pain, weight loss and worsening of diabetes 
appear, all of which are specific for malignancy, this generally indicates that the 
disease is at an advanced stage. The most investigated biomarker for malignancy 
prediction is CA 19–9 with 96.5–100% specificity. Based on metabolic biomarkers, 
Mayerle et al. (2018) introduce a novel approach for differential diagnose between 
CP and PC with an accuracy of 90% and a negative predictive value of 99.9%. Other 
promising markers are plasma micro-RNAs, monoclonal antibody PAM4, CD1D, 
which require further investigation. For the imaging diagnosis of PC, a CT scan is 
the technique of choice. Endoscopic ultrasound (EUS) could detect small pancreatic 
tumors in CP patients at a highest sensitivity compared to the available imaging and 
has the potential to detect early stage PC. The most appropriate cancer treatment 
(surgery, chemotherapy, radiation) depends on disease proliferation, defining the 
cancer as resectable, locally advanced or metastatic [144–149].
3.2 Pseudocysts
Pancreatic pseudocysts are common complication in CP with a frequency 
of 20–40%. The majority of patients are with alcoholic (70–80%) or idiopathic 
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etiology of CP (6–16%). The outcome of pseudocysts is assessed 6 weeks after 
acute episode occurring. In 40% of the pseudocysts there is a spontaneous 
resolution, another 40% of pseudocysts remain asymptomatic and in 20% of 
pseudocysts complications are observed (infection, rupture, bleeding, splenic 
vein thrombosis). Treatment is required if patients are symptomatic, if complica-
tions or obstruction of the stomach, duodenum or bile duct occur. Drainage of 
chronic pseudocysts may be performed by surgical, endoscopical or percutaneous 
approach. In asymptomatic pseudocysts with size above 5 cm, due to high pos-
sibility of complications, an endoscopical or surgical treatment is recommended. 
Percutaneous drainage should be avoided where possible. In chronic pseudocysts 
the endoscopical procedure is the treatment of choice due to lower mortality rate, 
improved quality of life and less length of hospitalization stay. Depending on 
size and localization, two endoscopic techniques are performed. A transpapillary 
approach should be considered in small pseudocysts with communication with the 
main pancreatic duct. The transmural approach (cystogastrostomy) is similar to 
the management of walled-off necrosis. It is more successful under echoendoscopic 
guidance. Double-pigtail plastic stents for at least 2 months are used for pseudocyst 
drainage. If a malignant genesis of the pseudocyst is suspected, surgery should 
follow [148, 150–156].
3.3 Splenic vein thrombosis
In 1920 Hirschfeldt first reported splenic vein thrombosis (SVT) as a pancre-
atitis consequence. Secondary involvement of the splenic vein endothelium by a 
nearby inflammation, compression by a pseudocyst or enlarged retroperitoneal/
pancreatic lymph nodes or initial injury could result in a splenic vein thrombosis 
and obstruction. The incidence of SVT in patients with CP is 1.5–41.6%. Sinistral 
portal hypertension and collateral development resulting in gastric and/or esopha-
geal varices are major risk factor for bleeding. Splenomegaly is reported in 42–54% 
of patients. Most patients are asymptomatic. Clinical features include gastrointes-
tinal bleeding in 12.3% of cases and abdominal pain. SVT is diagnosed primary by 
contrast-enhanced CT scan and/or upper endoscopy. Venous phase angiography 
is the gold standard confirmatory test, which could verify obstruction and col-
laterals routes. Based on the widely available CT scan most patients nowadays are 
diagnosed asymptomatic. The SVT management depends on existing symptoms 
including hypersplenic syndrome and history of variceal bleeding, which might 
require splenectomy with venous collateral outflow elimination and further variceal 
decompression. Gastric varices should be treated endoscopically by sclerotherapy, 
gastric banding [148, 157–162].
3.4 Duodenal obstruction
The duodenal obstruction is a rare complication in CP patients (1%) due to 
the anatomical relationship between the duodenum and the head of the pancreas. 
However, when analyzing operated patients with CP, the incidence of duodenal 
obstruction is higher—12%. Two types of obstruction are observed—transients 
during acute pancreatitis episodes and fixed by pseudocyst compression (dis-
cussed above) or fibrosclerotic process. Paraduodenal or groove pancreatitis 
is a rare clinic-pathological focal type of CP. The reported incidence of groove 
pancreatitis in resected CP patients ranges between 2.7 and 24.5%. It was first 
described by Becker in 1973 as a segmental pancreatitis. In 2004 Adsav and 
Zamboni unify the previously described terms under paraduodenal pancre-
atitis. The proposed pathophysiological mechanisms comprise functional/
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anatomical obstruction of papilla minor, Brunner’s gland hyperplasia around 
papilla minor, heterotopic intraduodenal pancreatic tissue or ductal variation. 
Two types paraduodenal pancreatitis are defined–cystic and solid. The cystic 
type is common with localization in the submucosa or lamina propria. The size 
may reach 10 cm, resulting in a bile duct obstruction. The solid type is rare and 
includes sheet-like and mass-like subtypes. According to several retrospective 
studies, the risk groups for paraduodenal pancreatitis development are middle-
aged men with alcohol consumption. Acute manifestation complains include 
postprandial abdominal pain (90–100%), nausea and vomiting (20%), gastric 
outlet syndrome. Chronic manifestations are weight loss (90%) and jaundice 
(20%). Perforation, bleeding, malignant degeneration of heterotopic pancreas are 
reported rare complications. EUS and MRCP are the preferred imaging methods 
for diagnostic evaluation. Treatment is based on a stepwise approach: (1) con-
servative treatment (analgesics, infusions, PPI, PERT, enteral nutrition, soma-
tostatin analogues); (2) endoscopic treatment; (3) surgery (Whipple procedure, 
pancreaticoduodenectomy, suprapapillar duodenal resection in isolated duodenal 
dystrophy, palliative gastrojejunostomy) [8, 148, 163–170].
3.5 Biliary obstruction
The incidence of distal common bile duct obstruction in patients with advanced 
chronic predominantly calcific pancreatitis with frequent acute episodes ranges 
from 3 to 46%. Pseudocysts are considered more as a risk factor than as a cause. 
Patients may be asymptomatic or with various spectrum of complains and 
 complications—pain, jaundice (transient or persistent for longer than 1 month), 
cholangitis and even sepsis, long-term risk of secondary biliary cirrhosis. 
Hyperbilirubinemia and twofold elevation of alkaline phosphatase levels for more 
than a month are used as reliable laboratory markers for common bile duct obstruc-
tion. CT scan provides information for the structural changes with high specificity 
and sensitivity. Based on the Caroli and Nora criteria, most patients with common 
bile duct stricture and CP are classified as type I and III. The treatment of choice 
depends on presence and severity and duration of symptoms; suspected malignant 
degeneration. To prevent progression to secondary biliary cirrhosis in patients with 
progressively increased alkaline phosphatase levels or persistent/with frequent 
relapses hyperbilirubinemia, endoscopic biliary stenting with self-expanding metal 
stents or multiple plastic stents or surgical procedures (pancreaticoduodenectomy, 
choledochojejunostomy, choledochoduodenostomy, hepaticojejunostomy) are 
required [148, 171–173].
3.6 Pseudoaneurysm
Pancreatic pseudoaneurysm as a rare life-threatening chronic pancreatitis 
complication occurs in 10% of patients, most often in those with pseudocysts. The 
pseudoaneurysm represents fibrous tissue containing hematoma and is mainly 
induced by enzymatic autodigestion or eroding of the nearby vessels, most frequent 
affecting the splenic artery. Most patients are asymptomatic, however, the first 
clinical manifestation might be bleeding caused by pseudoaneurysm rupture into 
gastrointestinal tract or other adjacent anatomic structures—peritoneal cavity, 
retroperitoneum, biliopancreatic ducts (hemosuccus pancreaticus). Shock and mul-
tiorgan failure further complicate the rupture. The mortality rate is about 40% and 
higher (90–100%) if pseudoaneurysm remains untreated. Worst outcome results 
have been shown in patients with pseudoaneurysm localization in the pancreas 
head. Angiography is the diagnostic tool of choice. Patients are nowadays treated 
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surgical, endovascular, by angioembolization and/or by percutaneous ultraso-
nographically guided thrombin injection. Treatment in diagnosed asymptomatic 
patients is recommended [174–179].
3.7 Pancreatic duct stones
In about 50% of patients chronic inflammation, gene predisposition and alcohol 
intake as a key cause change the pancreatic juice composition with pancreatic stone 
protein levels reduction, leading to formation of a nucleus with calcium deposi-
tion layers and later formation of a stone. The pancreatic duct stones are classified 
according to their number, localization and density to single or multiple calculi; 
stones in the pancreatic head, body and/or tail; localized in the main pancreatic 
duct, side-branches and/or parenchyma; radiopaque positive (the majority of 
cases), negative or mixed stones. The main pathological consequence is the duct 
obstruction with upstream dilatation, followed by ductal hypertension, which 
results in pain episodes, exocrine insufficiency due to reduce pancreatic juice flow 
into duodenum and impaired quality of life. Pancreatic duct stones are diagnosed 
by ERCP, CT or MRCP. However, MRCP is superior to ERCP for diagnosis as MRCP 
is a non-invasive alternative with no complications, providing detailed information 
about duct system and stone formations. Calculi removal could be performed by 
extracorporeal shock wave lithotripsy (ESWL), endoscopic techniques and surgery. 
According to the European Society of Gastrointestinal Endoscopy guidelines, 
first-line therapy for painful uncomplicated CP is ESWL combined or not with 
ERCP followed by spontaneous expulsion or endoscopic extraction of less than 
3 mm fragments. However, ESWL should be performed in centers with ESWL 
expertise. Best results from endoscopic techniques are observed in patients with 
early stages of CP with infrequent pain attacks, when calculi are less than 5 mm 
and have head localization with upstream main pancreatic duct dilatation. Alcohol 
and tobacco cessation improve the long-lasting results. Endoscopic techniques 
include ERCP followed by pancreatic sphincterotomy; stone retrieval with a bal-
loon, Dormia basket and/or forceps; dilatation and stent placement; mechanical 
lithotripsy. Endoscopy procedures together with ESWL improve the success to up 
to 90%. Direct visualization by pancreatoscopy followed by intraductal lithotripsy 
(Spyglass system) might be a future procedure of choice but today its use is limited. 
Surgery should be performed in patients with large or multiple calculi and stric-
tures, after unsuccessful prior endoscopy or ESWL procedures, as well as in those 
with no pain relief [8, 180–183].
4. Quality of life
With disease progression, patients with CP report for impaired overall quality 
of life. Many studies are conducted to investigate the contributing factors, leading 
to low QoL. Pain significantly correlates with overall health status, physical and 
mental subscales. Researchers emphasize the role of severity in contrast to pain 
frequency and pathophysiology. A large study of Machiado et al., including 1024 
CP patients, highlights constant pain as well as inability due to pain, smoking status 
and concomitant co-morbidities to worsen significantly QoL with negative influ-
ence on both physical and mental domains, leading to worsened social and family 
status and health resource utilization. Other assumed factors, which importance 
differs among the literature data, are disease duration, young age, women, tobacco 
and alcohol intake, underweight, pancreatic structural changes DM, PEI, prior 
endoscopic or surgical treatments. Psychologically conditioned disturbances 
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(depression, anxiety etc.) are linked most often to alcohol abuse and might lead to 
pain manifestation and impaired QoL. A study, which enrolled non-alcoholic CP 
patients, significant depressive syndromes were associated with poor QoL. By the 
newest concepts, the quality of life assessment is an essential part of the monitoring 
and the outcome in patients with CP. The European Organization for Research and 
Treatment of Cancer (EORTC QLQ ) has developed a quality of life questionnaire, 
containing 30 questions (EORTC QLQ-C30), including an additional question 
about steatorrhea. The questionnaire correlates with body weight gain and a 
reduced number of daily defecations related to malnutrition and maldigestion. The 
quality of life improved after adequate dosing in both newly diagnosed and patients 
receiving suboptimal PERT. Later, an additional panel of 26 questions concern-
ing pancreatic cancer patients (PAN26) was developed. In the United European 
Gastroenterology evidence based guidelines for the diagnosis and therapy of CP 
(HaPanEU), quality of life including pain should be assessed through validated 
questionnaires (SF-12, SF-36, EORTC QLQ C-30, GIQLI). However, effort should 
be point at improvement of variable factors as psychological status, tobacco, alcohol 
consumption and nutritional deficiencies in respect to improve QoL and further to 
delay disease progression, using therapeutic education and physical rehabilitation, 
behavioral support and medication [6, 99, 184–190].
5. Conclusion
Chronic pancreatitis is a progressive fibro-inflammatory syndrome, leading to 
abdominal pain and later to endocrine and exocrine insufficiency. Patients with CP 
might suffer a wide variety of complications, including pancreatic cancer, splenic 
vein thrombosis, pseudocysts, duodenal or biliary obstruction, pancreatic calculi, 
pseudoaneurysm and cardiovascular events. Proper individual up-to-date approach 
to diagnosis, treatment and follow-up of patients with CP are of fundamental 
importance to improve symptoms, detect early risk factors and reduce complica-
tions, which are associated with high mortality rate, and ensure better quality 
of life. Screening strategies development and their introduction into the clinical 
practice should be encouraged.
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